Genmab A/S (NASDAQ:GMAB) Position Lessened by American Century Companies Inc.

American Century Companies Inc. trimmed its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 19.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 320,575 shares of the company's stock after selling 76,505 shares during the period. American Century Companies Inc.'s holdings in Genmab A/S were worth $6,690,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Two Sigma Advisers LP raised its stake in shares of Genmab A/S by 84.1% in the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock worth $14,996,000 after buying an additional 280,900 shares in the last quarter. FMR LLC grew its holdings in Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after acquiring an additional 33,076 shares during the period. ABC Arbitrage SA acquired a new position in Genmab A/S during the fourth quarter worth about $3,692,000. AIMZ Investment Advisors LLC bought a new stake in Genmab A/S in the fourth quarter worth about $3,525,000. Finally, Raymond James Financial Inc. acquired a new stake in Genmab A/S in the 4th quarter valued at about $2,463,000. 7.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Finally, Truist Financial decreased their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $41.33.

Remove Ads

Genmab A/S Trading Down 1.2 %

NASDAQ:GMAB traded down $0.21 during trading hours on Tuesday, hitting $17.98. 1,942,131 shares of the stock traded hands, compared to its average volume of 1,000,986. The firm has a 50 day moving average price of $20.55 and a 200 day moving average price of $21.44. The firm has a market cap of $11.90 billion, a price-to-earnings ratio of 10.33, a PEG ratio of 2.65 and a beta of 1.07. Genmab A/S has a fifty-two week low of $17.77 and a fifty-two week high of $30.41.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Research analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.